Product
ONC-392
Aliases
A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc.
3 clinical trials
23 indications
Indication
Lung CancerIndication
Advanced Solid TumorIndication
Metastatic MelanomaIndication
Metastatic Head and Neck CarcinomaIndication
Renal Cell CarcinomaIndication
Colorectal CancerIndication
SarcomaIndication
Prostate CancerIndication
Ovarian CancerIndication
Small Cell Lung CancerIndication
Breast CancerIndication
Pancreatic CancerIndication
Stomach CancerIndication
Esophageal cancerIndication
Esophageal CancerIndication
Cervical CancerIndication
Adenoid Cystic CarcinomaIndication
Salivary Gland CancerIndication
Bladder CancerIndication
Primary Peritoneal CarcinomaIndication
Fallopian tube cancerClinical trial
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC)Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Randomized Study of ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Progressed on Androgen Receptor (AR) Pathway InhibitionStatus: Recruiting, Estimated PCD: 2026-06-30